Fig S1. The combination of BC250 and T cells treat mice in several ALL xenograft mouse models *in vivo*. **(A-C)** Immunodeficient NSG mice were intravenously inoculated with CD19(+) Daudi-luciferase (10^6), BV173-luciferase (10^6), or Raji-luciferase (0.5×10^6). Treatment was started after 3 (**C**, Raji) or 14 (**A** and **B**, Daudi and BV173) days of leukemia inoculation. Treatment was consisted of ATC injections (3 doses each 20×10^6 for Daudi, 1 dose of 8.8×10^6 for BV173, or 3 doses each 10×10^6 for Raji) with BC250 (CD3xCD19 BsAb) or the control BC119 (CD3xGD2 BsAb). Interleukin 2 was administered twice per week (1000 IU) to support ATC persistance. Leukemia growth was monitored using the IVIS bioluminescent imager.